Stock Track | REMEGEN Plummets 6.30% as Biotech Sector Faces Headwinds from Cooling BD Deals and Fading Rate Cut Hopes

Stock Track11-21

REMEGEN (09995.HK) shares plummeted 6.30% in Friday's trading session, reflecting broader pressures on the biotech sector in Hong Kong. The stock's sharp decline comes amid a constellation of factors weighing on biotech valuations, including a slowdown in business development deals and shifting expectations for U.S. interest rate cuts.

The Hong Kong-listed biotech sector faced significant headwinds, with several major players seeing substantial losses. HBM HOLDINGS-B (02142) led the declines with a 9.15% drop, followed by BRII-B (02137) at 7.56%, and INNOVENT BIO (01801) sliding 6.18%. This sector-wide downturn appears to be driven by emerging signs of cooling in biotech business development (BD) deals. Data from PharmaCube reveals that while China-related transactions grew by 129% year-on-year in the first half of 2025, growth decelerated to 64% in the first three quarters, indicating a slowdown in domestic biotech BD activity starting from the third quarter.

Adding to the pressure on biotech stocks, Morgan Stanley has withdrawn its forecast for a December Fed rate cut following a resilient U.S. September jobs report. The bank now anticipates rate reductions to begin in January 2026, potentially extending the high-interest rate environment. Analysts suggest that these fading rate cut expectations could further strain biotech valuations and dampen overseas life sciences investment, contributing to the sector's current downturn and REMEGEN's significant stock price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment